脑利钠肽(nesiritide)治疗心力衰竭。

文章的细节

引用

复制到剪贴板

贝当古P

脑利钠肽(nesiritide)治疗心力衰竭。

Cardiovasc药物启2002年冬季;20 (1):27-36。

PubMed ID

12070532 (在PubMed

]

文摘

过去十年脑利钠肽(BNP)成为心脏激素的临床兴趣诊断、预后和治疗患者的心力衰竭(HF)。法国早已确立的诊断潜力在疑似高频以及患者无症状患者左心室收缩功能障碍。获得的预后信息从心力衰竭和急性心肌梗死患者BNP水平似乎更有前途。Nesiritide合成肽,同源内源性BNP。这是一个平衡的血管舒张药和利尿利钠的性质。它会降低神经激素的水平升高造成的激活交感神经和高频renin-aldosterone系统。临床试验的结果,涉及2000多名失代偿心力衰竭患者现在可用。在这些试验nesiritide由单身或重复注射,以及持续的注入。Nesiritide已被证明,生产了一个强力的剂量相关性血管舒张效应在开始和持续快速输液。平衡血管舒张反映在全身血管阻力降低,肺动脉楔压和右心房压力。 No tachyphylaxis has been observed in these trials. Efficacy of nesiritide in the treatment of decompensated HF has been demonstrated. Trials comparing nesiritide with conventional treatment of decompensated HF showed that nesiritide compares favorably to standard agents. The safety profile has been excellent with a dose-dependent hypotension as the major side effect. Ventricular arrhythmia was not more frequent in patients treated with nesiritide than with placebo. Thus, nesiritide appears to be useful as a first-line agent in the treatment of patients with decompensated HF.

DrugBank数据引用了这篇文章

药物

Nesiritide